<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04771130</url>
  </required_header>
  <id_info>
    <org_study_id>BGB-11417-103</org_study_id>
    <nct_id>NCT04771130</nct_id>
  </id_info>
  <brief_title>A Study of BGB-11417 in Participants With Myeloid Malignancies</brief_title>
  <official_title>A Phase 1b/2, Open-Label, Dose Finding, and Expansion Study of the Bcl-2 Inhibitor BGB-11417 in Patients With Myeloid Malignancies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>BeiGene</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>BeiGene</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study will determine the safety, tolerability, recommended Phase 2 dose (RP2D) and&#xD;
      preliminary efficacy of BGB-11417 in combination with azacitidine in participants with acute&#xD;
      myeloid leukemia (AML) and myelodysplastic syndrome (MDS).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 24, 2021</start_date>
  <completion_date type="Anticipated">February 2024</completion_date>
  <primary_completion_date type="Anticipated">February 2022</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Part 1 And 2: Number Of Participants Experiencing Dose-limiting Toxicities (DLTs)</measure>
    <time_frame>Cycle 1 (Up to 28 days for non-hematologic DLTs and up to 42 days for hematologic DLTs)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 1 And 2: Number Of Participants Receiving BGB-11417 In Combination With Azacitidine Experiencing Treatment-emergent Adverse Events (TEAEs)</measure>
    <time_frame>Approximately 12 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 3 AML Cohort: Complete Remission (CR) Plus CR With Partial Hematologic Recovery (CRh) Rate</measure>
    <time_frame>Approximately 24 months</time_frame>
    <description>CR plus CRh will be defined as the proportion of participants whose best overall response (BOR) is CR plus CRh. BOR will be defined as the best response recorded from the first dose of study drug until data cut or the initiation of new anticancer treatment.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 3 MDS Cohort: Modified Overall Response (mOR) Rate</measure>
    <time_frame>Approximately 24 months</time_frame>
    <description>The mOR will be defined as the proportion of participants whose BOR is achieving CR, marrow complete remission (mCR), or partial remission (PR) at any time point during the study for myelodysplastic/myeloproliferative neoplasm (MDS/MPN).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 3 AML Cohort (DDI Sub-cohort): Area Under Plasma Concentration-time Curve (AUC) Of BGB-11417 When Coadministered With Posaconazole</measure>
    <time_frame>Cycle 2 Day 12 and Cycle 2 Day 20 (predose and 1, 4, 6, 8, and 24 hours postdose)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 3 AML Cohort (DDI Sub-cohort): Maximum Observed Plasma Concentration (Cmax) Of BGB-11417 When Coadministered With Posaconazole</measure>
    <time_frame>Cycle 2 Day 12 and Cycle 2 Day 20 (predose and 1, 4, 6, 8, and 24 hours postdose)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Parts 1 And 2 AML Cohort: CR Plus CRh Rate</measure>
    <time_frame>Approximately 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Parts 1 And 2 MDS Cohort: mOR Rate</measure>
    <time_frame>Approximately 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Parts 1 And 2: Cmax Of Azacitidine When Coadministered With BGB-11417</measure>
    <time_frame>Day 0 and 4 (Cycle 1) predose and at multiple time points up to 4 hours postdose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Parts 1 And 2: AUC From Time Zero To Time t (AUC0-t) Of Azacitidine When Coadministered With BGB-11417</measure>
    <time_frame>Day 0 and 4 (Cycle 1) predose and at multiple time points up to 4 hours postdose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Parts 1 And 2: AUC From Time Zero To Infinity (AUC0-inf) Of Azacitidine When Coadministered With BGB-11417</measure>
    <time_frame>Day 0 and 4 (Cycle 1) predose and at multiple time points up to 4 hours postdose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Parts 1 And 2: Apparent Total Clearance Of Drug From Plasma After Oral Administration (CL/F) Of Azacitidine When Coadministered With BGB-11417</measure>
    <time_frame>Day 0 and 4 (Cycle 1) predose and at multiple time points up to 4 hours postdose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Parts 1 And 2: Apparent Volume Of Distribution (Vz/F) Of Azacitidine When Coadministered With BGB-11417</measure>
    <time_frame>Day 0 and 4 (Cycle 1) predose and at multiple time points up to 4 hours postdose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Parts 1 And 2: Steady-state AUC From Time Zero To Time Of Last Measurable Concentration (AUClast,ss) Of BGB-11417 When Coadministered With Azacitidine</measure>
    <time_frame>Day 1-4 and 28 (Cycle 1) Day 5 (Cycle 2) predose and at multiple time points up to 8 hours postdose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Parts 1 And 2: Steady-state Cmax (Cmax,ss) Of BGB-11417 When Coadministered With Azacitidine</measure>
    <time_frame>Day 1-4 and 28 (Cycle 1) Day 5 (Cycle 2) predose and at multiple time points up to 8 hours postdose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Parts 1 And 2: Steady-state Trough Plasma Concentration (Ctrough,ss) Of BGB-11417 When Coadministered With Azacitidine</measure>
    <time_frame>Day 1-4 and 28 (Cycle 1) Day 5 (Cycle 2) predose and at multiple time points up to 8 hours postdose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Parts 1 And 2: Steady-state Time To Maximum Observed Plasma Concentration (tmax,ss) Of BGB-11417 When Coadministered With Azacitidine</measure>
    <time_frame>Day 1-4 and 28 (Cycle 1) Day 5 (Cycle 2) predose and at multiple time points up to 8 hours postdose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 3: Number Of Participants Receiving BGB-11417 In Combination With Azacitidine Experiencing TEAEs</measure>
    <time_frame>Approximately 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 3: CR</measure>
    <time_frame>Approximately 24 months</time_frame>
    <description>CR will be defined as the proportion of participants whose BOR is CR. BOR will be defined as the best response recorded from the first dose of study drug until data cut or the initiation of new anticancer treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 3 AML Cohort: CR With Incomplete Hematologic Recovery (CRi) Rate</measure>
    <time_frame>Approximately 24 months</time_frame>
    <description>CRi will be defined as the proportion of participants whose BOR is CRi.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 3 AML Cohort: Overall Response Rate (ORR)</measure>
    <time_frame>Approximately 24 months</time_frame>
    <description>The ORR will include participants whose BOR include CR, CRi, PR, and morphologic leukemia-free state.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 3 AML Cohort: Duration Of Response (DOR)</measure>
    <time_frame>Approximately 24 months</time_frame>
    <description>DOR will be defined as the time from the first response to disease progression documented after treatment initiation or death, whichever occurs first. DOR will include CR, CR plus CRi, overall response (OR), and CR plus CRh.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 3 AML Cohort: Time To Response (TTR)</measure>
    <time_frame>Approximately 24 months</time_frame>
    <description>TTR will be defined as the time from treatment initiation to the first documented response and will include CR, CR plus CRi, OR, and CR plus CRh.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 3: Event-free Survival (EFS)</measure>
    <time_frame>Approximately 24 months</time_frame>
    <description>EFS will be defined as the time from treatment initiation to disease progression, treatment failure, relapse (hematologic relapse for AML) for those who have treatment success, or death due to any cause, whichever happens first.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 3: Overall Survival (OS)</measure>
    <time_frame>Approximately 24 months</time_frame>
    <description>OS will be defined as the time from treatment initiation to death. OS will be analyzed using the same methods as the EFS analysis except for the censoring rules.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 3 MDS Cohort: Proportion Of Participants With Hematological Improvement-erythroid (HI-E)</measure>
    <time_frame>Approximately 24 months</time_frame>
    <description>The proportion of participants whose BOR is HI-E will be reported</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 3 MDS Cohort: Proportion Of Participants With Hematological Improvement-platelet (HI-P)</measure>
    <time_frame>Approximately 24 months</time_frame>
    <description>The proportion of participants whose BOR is HI-P will be reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 3 MDS Cohort: Proportion Of Participants With Hematological Improvement-neutrophil (HI-N)</measure>
    <time_frame>Approximately 24 months</time_frame>
    <description>The proportion of participants whose BOR is HI-N will be reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 3 MDS Cohort: Transfusion Independence</measure>
    <time_frame>Approximately 24 months</time_frame>
    <description>Transfusion independence will be defined as the proportion of participants whose BOR is transfusion independence. Transfusion independence will need to last for at least 56 consecutive days postbaseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 3: Ctrough,ss Of BGB-11417 When Coadministered With Azacitidine</measure>
    <time_frame>Cycle 1 Day 1 and Cycle 2 Day 5 (predose and 4 and 6 hours postdose)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 3 AML Cohort: Number Of Participants Receiving BGB-11417 In Combination With Posaconazole Experiencing TEAEs</measure>
    <time_frame>Approximately 24 months</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">110</enrollment>
  <condition>Acute Myeloid Leukemia</condition>
  <condition>Myelodysplastic Syndromes</condition>
  <condition>Myelodysplastic/Myeloproliferative Neoplasm</condition>
  <arm_group>
    <arm_group_label>Parts 1 and 2: AML Cohorts</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants with AML will receive BGB-11417 and azacitidine on a 28-day cycle.&#xD;
BGB-11417: Oral administration of 80 mg for 10 days, with a 4-day ramp-up for the first cycle.&#xD;
BGB-11417: Oral administration of 160 mg for 10 days, with a 4-day ramp-up for the first cycle.&#xD;
BGB-11417: Oral administration of 160 mg for 28 days, with a 4-day ramp-up for the first cycle.&#xD;
Azacitidine: Intravenous or subcutaneous administration for 7 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Experimental: Parts 1 and 2: MDS Cohorts</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants with MDS will receive BGB-11417 and azacitidine on a 28-day cycle.&#xD;
BGB-11417: Oral administration of 160 mg for 10 days, with a 4-day ramp-up for the first cycle.&#xD;
Azacitidine: Intravenous or subcutaneous administration for 7 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 3: AML Cohort</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants with AML will receive BGB-11417 and azacitidine on a 28-day cycle (or 10-day cycle as determined after Parts 1 and 2). A subset of the participants will receive a modified second cycle of treatment to explore drug-drug interactions (DDI) with posaconazole.&#xD;
BGB-11417: Oral administration at the RP2D determined in Part 2, with a 4-day ramp-up for the first cycle.&#xD;
Azacitidine: Intravenous or subcutaneous administration for 7 days. Posaconazole: Oral administration for 10 days on second cycle only.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 3: MDS Cohort</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants with MDS will receive BGB-11417 and azacitidine on a 28-day cycle.&#xD;
BGB-11417: Oral administration at the RP2D determined in Part 2 for 10 days, with a 4-day ramp-up for the first cycle.&#xD;
Azacitidine: Intravenous or subcutaneous administration for 7 days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BGB-11417</intervention_name>
    <description>Oral administration for 10 or 28 days on a 28-day cycle.</description>
    <arm_group_label>Experimental: Parts 1 and 2: MDS Cohorts</arm_group_label>
    <arm_group_label>Part 3: AML Cohort</arm_group_label>
    <arm_group_label>Part 3: MDS Cohort</arm_group_label>
    <arm_group_label>Parts 1 and 2: AML Cohorts</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Azacitidine</intervention_name>
    <description>Intravenous or subcutaneous administration for 7 days.</description>
    <arm_group_label>Experimental: Parts 1 and 2: MDS Cohorts</arm_group_label>
    <arm_group_label>Part 3: AML Cohort</arm_group_label>
    <arm_group_label>Part 3: MDS Cohort</arm_group_label>
    <arm_group_label>Parts 1 and 2: AML Cohorts</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Posaconazole</intervention_name>
    <description>Oral administration for 10 days on second cycle only.</description>
    <arm_group_label>Part 3: AML Cohort</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:&#xD;
&#xD;
          1. Confirmed diagnosis of one of the following by 2016 World Health Organization&#xD;
             criteria:&#xD;
&#xD;
               -  AML, nonacute promyelocytic leukemia&#xD;
&#xD;
               -  Treatment-naive (TN) MDS&#xD;
&#xD;
               -  TN MDS/MPN&#xD;
&#xD;
          2. Eastern Cooperative Oncology Group performance status of 0 to 2.&#xD;
&#xD;
          3. Adequate organ function defined as:&#xD;
&#xD;
               -  Creatinine clearance ≥ 45 milliliters/minute (mL/min) (or between 30 and 45&#xD;
                  mL/min in unfit AML cohort)&#xD;
&#xD;
               -  Adequate liver function&#xD;
&#xD;
          4. Life expectancy of &gt; 12 weeks.&#xD;
&#xD;
          5. Ability to comply with the requirements of the study.&#xD;
&#xD;
        Key Exclusion Criteria:&#xD;
&#xD;
          1. A diagnosis of acute promyelocytic leukemia.&#xD;
&#xD;
          2. Prior malignancy within the past 2 years, except for curatively treated localized skin&#xD;
             cancer, superficial bladder cancer, carcinoma in situ of the cervix or breast, or&#xD;
             localized Gleason score ≤ 6 prostate cancer.&#xD;
&#xD;
          3. Antecedent MPN including myelofibrosis, essential thrombocytosis, polycythemia vera,&#xD;
             or chronic myelogenous leukemia with or without BCR-ABL1 translocation and AML with&#xD;
             BCR-ABL1 translocation.&#xD;
&#xD;
          4. Prior therapy with a B-cell lymphoma-2 inhibitor or azacitidine.&#xD;
&#xD;
          5. Known central nervous system involvement by leukemia.&#xD;
&#xD;
        Note: Other protocol defined Inclusion/Exclusion criteria may apply.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David Simpson, MD</last_name>
    <role>Study Director</role>
    <affiliation>BeiGene</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>BeiGene</last_name>
    <phone>1.877.828.5568</phone>
    <email>clinicaltrials@beigene.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Pindara Private Hospital</name>
      <address>
        <city>Benowa</city>
        <zip>4217</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Gold Coast University Hospital</name>
      <address>
        <city>Gold Coast</city>
        <zip>4215</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Austin Hospital</name>
      <address>
        <city>Heidelberg</city>
        <zip>3084</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>The Alfred Hospital</name>
      <address>
        <city>Melbourne</city>
        <zip>3004</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>St. Vincent's Hospital Melbourne</name>
      <address>
        <city>Melbourne</city>
        <zip>3065</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Monash Health</name>
      <address>
        <city>Melbourne</city>
        <zip>3168</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Fiona Stanley Hospital</name>
      <address>
        <city>Murdoch</city>
        <zip>6150</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>One Clinical Research</name>
      <address>
        <city>Nedlands</city>
        <zip>6009</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Orange Health Service</name>
      <address>
        <city>Orange</city>
        <zip>2800</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Linear Clinical Research</name>
      <address>
        <city>Perth</city>
        <zip>6009</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Concord Hospital</name>
      <address>
        <city>Sydney</city>
        <zip>2139</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>St. George Hospital</name>
      <address>
        <city>Sydney</city>
        <zip>2217</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>John Flynn Hospital</name>
      <address>
        <city>Tugun</city>
        <zip>4224</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>North Shore Hospital</name>
      <address>
        <city>Auckland</city>
        <zip>0620</zip>
        <country>New Zealand</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Middlemore Hospital</name>
      <address>
        <city>Auckland</city>
        <zip>2025</zip>
        <country>New Zealand</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Wellington Regional Hospital</name>
      <address>
        <city>Wellington</city>
        <zip>6021</zip>
        <country>New Zealand</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>New Zealand</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>February 23, 2021</study_first_submitted>
  <study_first_submitted_qc>February 23, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 25, 2021</study_first_posted>
  <last_update_submitted>August 31, 2021</last_update_submitted>
  <last_update_submitted_qc>August 31, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>BGB-11417</keyword>
  <keyword>Azacitidine</keyword>
  <keyword>Posaconazole</keyword>
  <keyword>AML</keyword>
  <keyword>MDS</keyword>
  <keyword>MDS/MPN</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Myelodysplastic Syndromes</mesh_term>
    <mesh_term>Myeloproliferative Disorders</mesh_term>
    <mesh_term>Myelodysplastic-Myeloproliferative Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Posaconazole</mesh_term>
    <mesh_term>Azacitidine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

